Display options
Cite
Carter P, Alifrangis C, Cereser B, et al. Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. Oncotarget. 2017;9(5):6007-6014doi: 10.18632/oncotarget.23675.
Carter, P., Alifrangis, C., Cereser, B., Chandrasinghe, P., Del Bel Belluz, L., Fotopoulou, C., Frilling, A., Herzog, T., Moderau, N., Tabassum, N., Krell, J., & Stebbing, J. (2018). Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. Oncotarget, 9(5), 6007-6014. https://doi.org/10.18632/oncotarget.23675
Carter, Philip, et al. "Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy." Oncotarget vol. 9,5 (2018): 6007-6014. doi: https://doi.org/10.18632/oncotarget.23675
Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J. Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. Oncotarget. 2017 Dec 27;9(5):6007-6014. doi: 10.18632/oncotarget.23675. eCollection 2018 Jan 19. PMID: 29464050; PMCID: PMC5814190.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Dec 27;9(5):6007-6014. doi: 10.18632/oncotarget.23675. eCollection 2018 Jan 19.

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Oncotarget

Philip Carter, Costi Alifrangis, Biancastella Cereser, Pramodh Chandrasinghe, Lisa Del Bel Belluz, Christina Fotopoulou, Andreja Frilling, Thomas Herzog, Nina Moderau, Neha Tabassum, Jonathan Krell, Justin Stebbing

Affiliations

  1. Department of Surgery and Cancer, Imperial College, London, UK.
  2. Department of Oncology, University College Hospital, London, UK.
  3. Department of Surgery, University of Kelaniya, Kelaniya, Sri Lanka.
  4. Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, USA.
  5. University of Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, USA.

PMID: 29464050 PMCID: PMC5814190 DOI: 10.18632/oncotarget.23675

Abstract

Tumor molecular profiling has enabled selection of targeted therapies in a host of solid tumors. Here we used a retrospective clinical cohort, to evaluate the benefit of tailoring treatments for female genital tract malignancy, using tumor molecular profiles. Clinical outcome data for 112 patients was retrospectively separated into two groups. These either followed a matched treatment plan that incorporated at least one drug recommended according to their tumor profile and none that were expected to have no benefit (64 patients), or was unmatched with suggested treatments and received at least one drug that was anticipated to lack benefit for that tumor (48 patients). In the group of patients whose drugs matched those recommended by molecular profiling of their tumor, their overall survival was 593 days on average, compared to 449 days for patients that did not; removing drugs predicted to have no benefit from treatment regimens received after profiling increased survival by 144 days on average (

Keywords: cancer treatment; female genital tract malignancy; tumor profiling

Conflict of interest statement

CONFLICTS OF INTEREST We have no conflicts of interest.

References

  1. Obstet Gynecol Clin North Am. 2012 Jun;39(2):233-53 - PubMed
  2. Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):293-309 - PubMed
  3. Gynecol Oncol. 2005 Mar;96(3):671-7 - PubMed
  4. Int J Gynecol Cancer. 2016 Jan;26(1):2-30 - PubMed
  5. Lancet. 2005 Aug 6-12;366(9484):491-505 - PubMed
  6. Semin Reprod Med. 2010 Jan;28(1):81-90 - PubMed
  7. PLoS One. 2016 Feb 09;11(2):e0148912 - PubMed
  8. Eur J Cancer. 2014 Nov;50(17 ):3003-10 - PubMed
  9. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  10. Anticancer Res. 2010 Apr;30(4):1341-5 - PubMed
  11. Clin Cancer Res. 2011 Apr 15;17 (8):2538-48 - PubMed
  12. Oncol Rep. 2007 Nov;18(5):1051-9 - PubMed
  13. Endocr Rev. 2013 Feb;34(1):130-62 - PubMed
  14. Adv Anat Pathol. 2009 Sep;16(5):267-82 - PubMed

Publication Types

Grant support